Kelli A. Connolly

Kelli A. Connolly

Auto-generated profile, based on publicly available information

Kelli A. Connolly

Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06519, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2021 in Science Immunology
Verified
Journal Article
Open access
KCKelli A. Connolly
Kelli A. Connolly
MKManik Kuchroo
Manik Kuchroo
AVAarthi Venkat
Aarthi Venkat
AKAchia Khatun
Achia Khatun
JWJiawei Wang
Jiawei Wang
NJNikhil S. Joshi
Nikhil S. Joshi
Tumor-specific CD8 + T cells in stable tumor-draining lymph node reservoir are clonally and developmentally related to those in tumors.

14 February 2025 in Science
Verified
Journal Article
Closed access
EFEric Fagerberg
Eric Fagerberg
JAJohn Attanasio
John Attanasio
CDChristine Dien
Christine Dien
JSJaiveer Singh
Jaiveer Singh
EKEmily A. Kessler
Emily A. Kessler
NJNikhil S. Joshi
Nikhil S. Joshi
Naïve CD8 T cells have the potential to differentiate into a spectrum of functional states during an immune response. How these developmental decisions are made and what mechanisms exist to suppress differentiation toward alternative fates remains unclear. We employed in vivo CRISPR-Cas9–based perturbation sequencing to assess the role of ~40 transcription factors (TFs) and epigenetic modulators in T cell fate decisions. Unexpectedly, we found that knockout of the TF Klf2 resulted in aberrant differentiation to exhausted-like CD8 T cells during acute infection. KLF2 was required to suppress the exhaustion-promoting TF TOX and to enable the TF TBET to drive effector differentiation. KLF2 was also necessary to maintain a polyfunctional tumor-specific progenitor state. Thus, KLF2 provides effector CD8 T cell lineage fidelity and suppresses the exhaustion program.

16 September 2021 in Cell Reports Methods
Verified
Journal Article
Open access
BFBrittany Fitzgerald
Brittany Fitzgerald
KCKelli A. Connolly
Kelli A. Connolly
CCCan Cui
Can Cui
EFEric Fagerberg
Eric Fagerberg
DMDylan L. Mariuzza
Dylan L. Mariuzza
NJNikhil S. Joshi
Nikhil S. Joshi
Kras-driven lung adenocarcinoma (LUAD) is the most common lung cancer. A significant fraction of patients with Kras-driven LUAD respond to immunotherapy, but mechanistic studies of immune responses against LUAD have been limited because of a lack of immunotherapy-responsive models. We report the development of the immunogenic KP × NINJA (inversion inducible joined neoantigen) (KP-NINJA) LUAD model. This model allows temporal uncoupling of antigen and tumor induction, which allows one to wait until after infection-induced inflammation has subsided to induce neoantigen expression by tumors. Neoantigen expression is restricted to EPCAM+ cells in the lung and expression of neoantigen was more consistent between tumors than when neoantigens were encoded on lentiviruses. Moreover, tumors were infiltrated by tumor-specific CD8 T cells. Finally, LUAD cell lines derived from KP-NINJA mice were immunogenic and responded to immune checkpoint therapy (anti-PD1 and anti-CTLA4), providing means for future studies into the immunobiology of therapeutic responses in LUAD.